- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05263609
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib in Metastatic Renal Cell Cancer: A Response Adapted Study (OPTIMAX)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years at the time of consent.
- ECOG performance status ≤1 (Appendix A) within 28 days prior to registration.
- Participants must have histologically or cytologically confirmed clear-cell or non-clear cell renal cell carcinoma.
- Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.137.
- Both previously untreated and treated patients will be eligible for participation with no limit on number of prior lines of therapy. Prior therapy with checkpoint inhibitors and/or axitinib for advanced disease is not allowed. Patients who have received treatment with prior checkpoint inhibitors (anti-PD-1/L1 or anti- CTLA-4) or VEGF receptor tyrosine kinase inhibitors in neoadjuvant/adjuvant setting are eligible for inclusion if time from treatment discontinuation to disease recurrence is more than 1 year.
- Adequately controlled blood pressure (BP), with or without antihypertensive medications, defined as BP ≤150/90 mmHg at screening and no change in antihypertensive medications within 1 week before the Cycle 1/Day 1.
- Willingness of the patient to undergo mandatory fresh tumor biopsy on study unless determined medically unsafe or not feasible by the treating investigator. If a target lesion is biopsied at screening, this lesion must be followed as non-target lesion after the biopsy unless it is the patient's only target lesion.
- Participants must have normal organ and marrow function as defined below within 42 days prior to first study treatment
- A female participant is eligible to participate if they are not pregnant (negative urine or serum pregnancy test within 42 days prior to registration), not breastfeeding, and at least one of the following conditions applies: a.) Not a woman of childbearing potential (WOCBP) OR b.) A WOCBP who agrees to follow tcontraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
- A male participant must agree to use contraception as of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
Exclusion Criteria:
- Participants who have had prior systemic checkpoint inhibitors (anti-PD-1/L1 or anti-CTLA-4) and/or axitinib for the management of metastatic RCC.
- Participants who have had any type of anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy, small molecule kinase inhibitor or chemotherapy) within 2 weeks prior to enrollment on the study.
- Radiotherapy for RCC within 14 days of first study treatment with the exception of a single fraction of radiation administered for palliation of symptoms.
- Presence of any toxicities attributed to prior anti-cancer therapy that are not resolved to ≤ grade 1 (National Cancer Institute Common Terminology Criteria for Adverse Events CTCAE version v5.0) or baseline before administration of study drug38 with the exception of alopecia or grade 2 fatigue.
- Participants who are receiving systemic immunosuppressive medications within 2 weeks of first study dose, including but not limited to: prednisone, dexamethasone, cyclosporin, azathioprine, methotrexate, thalidomide, anti-tumor necrosis factor (TNF) agents
- Treatment with short term (<7 days), or low-dose systemic immunosuppressant medications (≤ 10 mg prednisone/day equivalent) within 2 weeks of first study dose is permitted.
- Patients with adrenal insufficiency on physiologic replacement doses of steroids (≤ 10 mg prednisone equivalent) may be enrolled.
- The use of inhaled, topical, ocular or intra-articular corticosteroids and mineralocorticoids are allowed for other non-RCC co-morbidities.
- Any active or recent history (within 6 months of first study dose) of autoimmune disease or syndrome that requires systemic corticosteroids (>10 mg daily prednisone equivalent) or immunosuppressive medications.
- Patients with low risk disorders, such as vitiligo, controlled type I diabetes mellitus, hypo- or hyperthyroid disease, or surgical adrenal insufficiency requiring hormone replacement therapy, are permitted to enroll. Discuss with PI any additional disorders not on this list that may qualify.
- Participants with known untreated or symptomatic metastases to the brain, spinal cord or leptomeninges. Patients may be eligible if stable intracranial disease for at least 4 weeks before first study treatment as documented by magnetic resonance imaging (MRI) or computerized tomography (CT) imaging and if no ongoing requirement for steroids.
- Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on screening ECG > 480 msec.
- Bleeding or thrombotic disorders or patients at risk for severe hemorrhage. Gastrointestinal malabsorption, gastrointestinal anastomosis, fistula, or any other condition that might affect the absorption of axitinib.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or axitinib.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Known active or chronic hepatitis B infection (defined as having a positive hepatitis B surface antigen (HBsAg) test at screening).
- Patient with past or resolved hepatitis B infection (defined as having a negative HBsAg test and positive antibody to hepatitis B core antigen test) are eligible. Hepatitis B viral DNA must be obtained in patients with positive hepatitis B core antibody prior to first treatment start.
- Patients with active/chronic viral hepatitis C are ineligible because of the potential for pharmacokinetic interactions.
- Patients with positive hepatitis C antibody test are eligible if PCR is negative for hepatitis C viral DNA.
- Known HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions and an increased risk of lethal infections when treated with immunosuppressive therapy for immune related adverse events.
- Administration of a live vaccine or live-attenuated vaccine within 30 days of first dose of study treatment. Administration of killed vaccine is allowed.
- Receipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment. Patients receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligible. Empiric antibiotics given without subsequent proof of infection will not be counted as ineligible.
- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- Prior allogenic stem cell or solid organ transplant.
- Other malignancies with the exception of those with negligible risk of metastases or death in view of the treating investigator and/or treated with expected curative outcome. Examples of (but not limited to) permitted treated cancers: carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive urothelial carcinoma not requiring current therapy.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm A
Arm A (CR/oPR on pembrolizumab monotherapy): Patients will continue pembrolizumab monotherapy if CR/oPR on initial treatment with pembrolizumab monotherapy. If CR/oPR persists at 8 cycles (24 weeks) after assignment on arm A, pembrolizumab break will commence. Patients will be monitored for disease progression with imaging every 9 weeks (+/- 1 week). If patients develop progression, pembrolizumab will be resumed and continued until subsequent PD. At that point, axitinib may be added to pembrolizumab as part of the study or patients may discontinue study treatment per the treating investigator's discretion. |
If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
|
Experimental: Arm B
Arm B (sPR/SD/PD): Patients with sPR, SD or PD after 6 cycles of pembrolizumab monotherapy will be started on axitinib in addition to continuing pembrolizumab. If patients develop subsequent PD, treatment will be discontinued. If the subsequent scans show SD/PR/CR, the combination treatment will be continued until PD or unacceptable toxicity. |
If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proportion of Patient Response
Periodo de tiempo: 2 year
|
To catalogue the number and proportion of patients with persistence of complete response or optimal partial response at 1 year after the discontinuation of pembrolizumab
|
2 year
|
Objective Response Rate After Axitinib
Periodo de tiempo: 2 year
|
To assess the objective response rate after addition of axitinib in patients with a suboptimal partial response, stable disease or progressive disease on pembrolizumab monotherapy alone.
|
2 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Objective Response Rate after Pembrolizumab
Periodo de tiempo: 2 year
|
To determine the objective response rate (ORR: CR +oPR + sPR) after 6 cycles of primary treatment with pembrolizumab
|
2 year
|
Duration of Response
Periodo de tiempo: 2 year
|
To determine duration of CR or oPR To determine progression-free survival (PFS) from pembrolizumab initiation To determine treatment-free survival (TFS) from pembrolizumab discontinuation To assess safety and toxicity according to NCI CTCAE v5 |
2 year
|
Overall Survival
Periodo de tiempo: 2 year
|
To determine overall survival (OS) from pembrolizumab initiation
|
2 year
|
Proportion of patients that experience toxicity
Periodo de tiempo: 2 year
|
To assess safety and toxicity according to NCI CTCAE v5 on pembrolizumab monotherapy
|
2 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Abhishek Tripathi, MD, Stephenson Cancer Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades Renales
- Enfermedades urológicas
- Adenocarcinoma
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Neoplasias Renales
- Carcinoma De Célula Renal
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Inhibidores de la proteína quinasa
- Pembrolizumab
- Axitinib
Otros números de identificación del estudio
- OU-SCC-OPTIMAX
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de células renales
-
Ludwig Institute for Cancer ResearchMemorial Sloan Kettering Cancer CenterTerminadoCancer de RIÑON | Carcinoma de células renales | Cáncer renal | Neoplasia RenalEstados Unidos
-
Aesculap AGTerminadoCancer de RIÑON | Nefrolitiasis | Cancer de prostata | Nefritis | Lesión renal | Hidronefrosis | Anomalía congénita del riñón | Tuberculosis renalAlemania
-
Five Eleven Pharma, Inc.Activo, no reclutandoCancer de prostata | Cáncer renalEstados Unidos
-
SCRI Development Innovations, LLCGenentech, Inc.TerminadoCancer de RIÑON | Cáncer renalEstados Unidos
-
National Cancer Institute (NCI)Terminado
-
National Cancer Institute (NCI)TerminadoCancer de RIÑON | Cáncer renalEstados Unidos
-
Institut du Cancer de Montpellier - Val d'AurelleLigue contre le cancer, FranceReclutamiento
-
Nazmy Edward SeifReclutamientoInsuficiencia renal | Cancer de prostata | Cirugía | Cáncer de vejiga | Lesión renal agudaEgipto
-
SCRI Development Innovations, LLCNovartis; Genentech, Inc.TerminadoCancer de RIÑONEstados Unidos
-
Leiden University Medical CenterMerck Sharp & Dohme LLCTerminadoCancer de prostata | Cáncer renalPaíses Bajos
Ensayos clínicos sobre Pembrolizumab
-
Incyte CorporationMerck Sharp & Dohme LLCTerminadoMelanomaEstados Unidos, Francia, Italia, Reino Unido, España, Bélgica, Israel, México, Japón, Canadá, Países Bajos, Suecia, Corea, república de, Australia, Federación Rusa, Chile, Alemania, Polonia, Irlanda, Nueva Zelanda, Dinamarca, Suiza, Su...
-
Merck Sharp & Dohme LLCTerminado
-
Acerta Pharma BVMerck Sharp & Dohme LLCTerminadoCarcinoma urotelial metastásicoEstados Unidos
-
University Medical Center GroningenTerminado
-
HUYABIO International, LLC.Activo, no reclutandoCáncer de pulmón de células no pequeñasEstados Unidos
-
Prof. Dr. Matthias PreusserDesconocidoEstudio sobre pembrolizumab para el linfoma primario recurrente del sistema nervioso central (PCNSL)Linfoma primario del sistema nervioso centralAustria
-
Yonsei UniversityAún no reclutandoMelanoma de las mucosas | Melanoma acralCorea, república de
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsReclutamientoCáncer colonrectal | Cáncer de endometrioPaíses Bajos
-
Michael BoyiadzisMerck Sharp & Dohme LLCTerminadoLeucemia mieloide agudaEstados Unidos